Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Evotec Se (EVTCY)

Evotec Se (EVTCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme AccessWire - Mon Mar 21, 2022

- FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC - PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR...

EVTCY : 22.9600 (-0.04%)
EVO : 7.24 (+3.28%)
Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology AccessWire - Tue Jan 25, 2022

- PARTNERSHIP LEVERAGES EVOTEC'S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS - AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS HAMBURG,...

EVTCY : 22.9600 (-0.04%)
EVO : 7.24 (+3.28%)
Evotec and Lilly Enter into Drug Discovery Collaboration in Metabolic Diseases AccessWire - Tue Jan 18, 2022

- COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS - LILLY HAS THE RIGHT...

EVTCY : 22.9600 (-0.04%)
EVO : 7.24 (+3.28%)
Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach AccessWire - Tue Jan 11, 2022

- EXPANSION LEVERAGES A PROPRIETARY EVOTEC PLATFORM IN THE FIELD OF TARGETED PROTEIN DEGRADATION TO TACKLE SELECTED TARGETS WITH RELEVANCE FOR A RANGE OF NEURODEGENERATIVE CONDITIONS - EVOTEC RECEIVES...

EVTCY : 22.9600 (-0.04%)
BMY : 47.84 (-0.87%)
Evotec Receives US$ 18 M Grant for Women's Health AccessWire - Thu Dec 16, 2021

- GRANT WILL SUPPORT FULLY INTEGRATED DRUG DISCOVERY PROGRAMME FROM SCREENING TO PRE-CLINICAL DEVELOPMENT CANDIDATE - PROJECT LEVERAGES EVOTEC'S WOMEN'S HEALTH PLATFORM AND AI/ML MOLECULAR DESIGN TOOLS...

EVTCY : 22.9600 (-0.04%)
Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership AccessWire - Thu Nov 18, 2021

- EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM - PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND...

EVTCY : 22.9600 (-0.04%)
EVO : 7.24 (+3.28%)
CMLTU : 8.87 (-6.53%)
Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb AccessWire - Wed Nov 10, 2021

- THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / November 10, 2021 / Evotec SE (Frankfurt Stock Exchange:EVT,...

EVTCY : 22.9600 (-0.04%)
EVO.AX : 0.685 (-0.72%)
BMY : 47.84 (-0.87%)
Evotec SE Announces Placement of Its Public Offering of American Depositary Shares AccessWire - Wed Nov 3, 2021

HAMBURG, GERMANY / ACCESSWIRE / 3 November 2021 / Evotec SE's (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) management board today decided - with the approval of its supervisory...

EVTCY : 22.9600 (-0.04%)
Evotec SE To Announce Results for the First Nine Months 2021 On 11 November 2021 AccessWire - Wed Nov 3, 2021

HAMBURG, GERMANY / ACCESSWIRE / November 3, 2021 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the first nine months 2021 on Thursday,...

EVTCY : 22.9600 (-0.04%)
Evotec SE: Announces Launch of Public Offering of American Depositary Shares AccessWire - Tue Oct 26, 2021

HAMBURG, GERMANY / ACCESSWIRE / October 26, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has commenced a public offering in the United States...

EVTCY : 22.9600 (-0.04%)

Barchart Exclusives

This Outperforming Dividend Aristocrat Could Rally Another 22%, Says Analyst Barchart - Wed Apr 17, 6:30PM CDT
With a track record of 30 years of dividend increases, this industrial stock is also delivering some outsized capital appreciation to shareholders lately. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot